ACOG — Alpha Cognition Share News
0.000.00%
Last trade - 00:00- $184.02m
- $142.64m
- $10.22m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:00 AM
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental
Alpha Cognition surges as study shows Alzheimer’s drug improves cognition, behavior
Brief: Alpha Cognition Reports Positive Top-Line Results Of Zunveyl® In Alzheimer’s Disease
Brief: Alpha Cognition Reports First Quarter 2026 Financial Results And Provides Operational Update
Brief: Alpha Cognition Appoints Bethany Sensenig
Brief: Alpha Cognition Inc - Enters Settlement Agreement With Galantos Pharma On April 10, 2026 - SEC Filing
Brief: Alpha Cognition Receives Issued U.S. Patent For Alpha-1062 For Treatment Of Traumatic Brain Injury
Brief: Alpha Cognition Announces First Patient Enrolled In Beacon Real-World Effectiveness Study
Brief: Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities And 2025 Commercial Execution
Brief: Alpha Cognition Inc Announces Pricing Of Oversubscribed Underwritten Public Offering Of 5.6 Mln Common Shares At $6.25 Per Share
Brief: Alpha Cognition Announces Proposed Public Offering Of Common Shares
Brief: Alpha Cognition Files For Mixed Shelf Of Up To $250 Million
Brief: Alpha Cognition Announces Partner China Medical System Has NDA Accepted In China For The Review Of Zunveyl® (Benzgalantamine) For Alzheimer’S Disease
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign
U.S. STOCKS ON THE MOVE-Ralph Lauren, Gold miners, Aditxt
Alpha Cognition rises on commercial launch of Alzheimer's drug